Early biologic treatment versus conventional treatment for the management of Crohn's disease a review of comparative clinical effectiveness and cost-effectiveness
Given the theorized benefits of a top-down approach (early use of biologics), there is growing interest in its clinical effectiveness, safety, and cost-effectiveness compared to a conventional treatment approach, both in children and adults. As such, this report sought to summarize the evidence rega...
| Main Authors: | , |
|---|---|
| Corporate Authors: | , |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
CADTH
February 13, 2019, 2019
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: peer-reviewed summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Given the theorized benefits of a top-down approach (early use of biologics), there is growing interest in its clinical effectiveness, safety, and cost-effectiveness compared to a conventional treatment approach, both in children and adults. As such, this report sought to summarize the evidence regarding the clinical and cost-effectiveness of early biologic therapy compared to conventional treatment for Crohn's disease in children and adults. This is an upgrade of a previous CADTH rapid response titled "Early Treatment versus Conventional Treatment for the Management of Luminal Crohn's Disease: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness" |
|---|---|
| Physical Description: | 1 PDF file (47 pages) illustrations |